Bessemer Group Inc Cassava Sciences Inc Transaction History

Bessemer Group Inc

$60.7 Billion
Q3 2024

A detailed history of Bessemer Group Inc transactions in Cassava Sciences Inc stock. As of the latest transaction made, Bessemer Group Inc holds 55 shares of SAVA stock, worth $210. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Holding current value

$210

% of portfolio

0.0%

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2024 Nov 12, 2024	BUY	$9.57 - $35.08 $526 - $1,929	55 New	55 $2,000
Q2 2021 Aug 06, 2021	BUY	$32.15 - $89.72 $4,822 - $13,458	150 New	150 $13,000

Others Institutions Holding SAVA

# of Institutions

207

Shares Held

14M

Call Options Held

2.98M

Put Options Held

6.57M

Black Rock Inc. New York, NY

3.22M
Shares

$12.3 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

2.52M
Shares

$9.66 Million
0.0% of portfolio
State Street Corp Boston, MA

1.16M
Shares

$4.45 Million
0.0% of portfolio
Geode Capital Management, LLC Boston, MA

1.01M
Shares

$3.86 Million
0.0% of portfolio
Gallacher Capital Management LLC Lone Tree, CO

580K
Shares

$2.22 Million
7.83% of portfolio

View Full List

About CASSAVA SCIENCES INC

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $154M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

More about SAVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bessemer Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Bessemer Group Inc with notifications on news.

Account